| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cryptosporidium parvum | 12 | 2024 | 21 | 4.500 |
Why?
|
| IMP Dehydrogenase | 17 | 2025 | 26 | 4.060 |
Why?
|
| Enzyme Inhibitors | 24 | 2025 | 559 | 3.640 |
Why?
|
| Protein Kinase Inhibitors | 26 | 2024 | 614 | 3.610 |
Why?
|
| Structure-Activity Relationship | 49 | 2023 | 553 | 2.540 |
Why?
|
| Cryptosporidiosis | 9 | 2024 | 35 | 2.270 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 5 | 2021 | 7 | 2.110 |
Why?
|
| Pyridines | 8 | 2021 | 258 | 1.810 |
Why?
|
| Aporphines | 4 | 2021 | 4 | 1.710 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 8 | 2024 | 23 | 1.480 |
Why?
|
| Molecular Structure | 24 | 2021 | 312 | 1.440 |
Why?
|
| Protein Kinases | 3 | 2024 | 313 | 1.380 |
Why?
|
| Pyrazoles | 10 | 2018 | 354 | 1.350 |
Why?
|
| Antiparasitic Agents | 4 | 2020 | 28 | 1.210 |
Why?
|
| Palladium | 5 | 2015 | 20 | 1.210 |
Why?
|
| Cryptosporidium | 3 | 2024 | 27 | 1.100 |
Why?
|
| Stereoisomerism | 13 | 2021 | 109 | 1.090 |
Why?
|
| Imidazoles | 11 | 2015 | 219 | 1.060 |
Why?
|
| Drug Design | 9 | 2021 | 159 | 1.030 |
Why?
|
| Carbolines | 3 | 2012 | 8 | 1.000 |
Why?
|
| Indoles | 10 | 2013 | 200 | 1.000 |
Why?
|
| Nod2 Signaling Adaptor Protein | 3 | 2021 | 21 | 0.920 |
Why?
|
| Antineoplastic Agents | 7 | 2021 | 1802 | 0.910 |
Why?
|
| Drug Discovery | 10 | 2018 | 177 | 0.870 |
Why?
|
| Pyrimidinones | 2 | 2024 | 62 | 0.860 |
Why?
|
| High-Throughput Screening Assays | 13 | 2015 | 117 | 0.850 |
Why?
|
| Aminopyridines | 3 | 2020 | 64 | 0.810 |
Why?
|
| Anilides | 2 | 2020 | 52 | 0.770 |
Why?
|
| Benzoxazoles | 5 | 2022 | 11 | 0.760 |
Why?
|
| Microsomes, Liver | 6 | 2017 | 98 | 0.710 |
Why?
|
| Signal Transduction | 13 | 2025 | 4656 | 0.710 |
Why?
|
| Binding Sites | 14 | 2025 | 1135 | 0.710 |
Why?
|
| Pyrroles | 4 | 2011 | 189 | 0.700 |
Why?
|
| Models, Molecular | 19 | 2025 | 1060 | 0.700 |
Why?
|
| Lewis Acids | 1 | 2021 | 2 | 0.700 |
Why?
|
| Dimerization | 1 | 2021 | 137 | 0.680 |
Why?
|
| Pyridazines | 5 | 2015 | 49 | 0.680 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2011 | 51 | 0.680 |
Why?
|
| Necrosis | 8 | 2012 | 193 | 0.680 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 5 | 2015 | 12 | 0.670 |
Why?
|
| Nod Signaling Adaptor Proteins | 1 | 2020 | 1 | 0.640 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2021 | 584 | 0.640 |
Why?
|
| Aniline Compounds | 2 | 2011 | 23 | 0.630 |
Why?
|
| Plant Extracts | 1 | 2021 | 127 | 0.630 |
Why?
|
| Indazoles | 2 | 2012 | 36 | 0.630 |
Why?
|
| Vasodilator Agents | 1 | 2021 | 197 | 0.620 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 267 | 0.590 |
Why?
|
| Molecular Docking Simulation | 5 | 2021 | 147 | 0.590 |
Why?
|
| Antiprotozoal Agents | 3 | 2024 | 41 | 0.580 |
Why?
|
| Protein Binding | 16 | 2025 | 1650 | 0.570 |
Why?
|
| Quinolones | 3 | 2017 | 58 | 0.570 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 265 | 0.570 |
Why?
|
| Animals | 63 | 2025 | 33697 | 0.540 |
Why?
|
| Thiazoles | 3 | 2017 | 112 | 0.540 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 57 | 0.530 |
Why?
|
| Catalysis | 9 | 2013 | 138 | 0.520 |
Why?
|
| Quinolines | 5 | 2013 | 115 | 0.520 |
Why?
|
| Apoptosis | 6 | 2021 | 1830 | 0.520 |
Why?
|
| Cyclin-Dependent Kinase 5 | 5 | 2013 | 12 | 0.510 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 655 | 0.510 |
Why?
|
| Crystallography, X-Ray | 7 | 2025 | 364 | 0.500 |
Why?
|
| Alkaloids | 3 | 2015 | 36 | 0.500 |
Why?
|
| Peptides, Cyclic | 1 | 2016 | 46 | 0.490 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2016 | 64 | 0.480 |
Why?
|
| Mice | 39 | 2025 | 18172 | 0.480 |
Why?
|
| Humans | 80 | 2025 | 130123 | 0.480 |
Why?
|
| Micromonospora | 1 | 2015 | 1 | 0.470 |
Why?
|
| Hypnotics and Sedatives | 3 | 2011 | 131 | 0.470 |
Why?
|
| Depsipeptides | 1 | 2015 | 15 | 0.460 |
Why?
|
| Disulfides | 1 | 2015 | 60 | 0.460 |
Why?
|
| Pyrimidines | 6 | 2018 | 454 | 0.450 |
Why?
|
| Neurodegenerative Diseases | 3 | 2012 | 281 | 0.440 |
Why?
|
| Acetanilides | 1 | 2014 | 8 | 0.440 |
Why?
|
| Coumarins | 1 | 2014 | 23 | 0.440 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2013 | 127 | 0.430 |
Why?
|
| Ketones | 2 | 2012 | 26 | 0.420 |
Why?
|
| Cyclization | 6 | 2017 | 16 | 0.410 |
Why?
|
| Cell Line | 15 | 2017 | 2554 | 0.410 |
Why?
|
| Inhibitory Concentration 50 | 6 | 2024 | 83 | 0.400 |
Why?
|
| Small Molecule Libraries | 5 | 2013 | 131 | 0.400 |
Why?
|
| Cell Line, Tumor | 12 | 2021 | 3714 | 0.400 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2022 | 432 | 0.380 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2012 | 219 | 0.380 |
Why?
|
| Isatin | 2 | 2010 | 2 | 0.370 |
Why?
|
| Activin Receptors, Type I | 4 | 2018 | 33 | 0.370 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2012 | 31 | 0.360 |
Why?
|
| GABA Agonists | 1 | 2011 | 14 | 0.350 |
Why?
|
| Urea | 1 | 2012 | 219 | 0.350 |
Why?
|
| Alzheimer Disease | 7 | 2025 | 875 | 0.340 |
Why?
|
| Sulfones | 2 | 2021 | 72 | 0.340 |
Why?
|
| Phenols | 4 | 2020 | 73 | 0.330 |
Why?
|
| Indolizines | 1 | 2010 | 10 | 0.330 |
Why?
|
| Benzimidazoles | 1 | 2012 | 155 | 0.330 |
Why?
|
| Amides | 2 | 2013 | 81 | 0.330 |
Why?
|
| Survival of Motor Neuron 2 Protein | 3 | 2017 | 13 | 0.330 |
Why?
|
| Acridines | 1 | 2010 | 7 | 0.320 |
Why?
|
| Central Nervous System | 1 | 2012 | 269 | 0.320 |
Why?
|
| Sulfides | 2 | 2013 | 21 | 0.320 |
Why?
|
| Fluorescent Dyes | 2 | 2021 | 247 | 0.310 |
Why?
|
| Acetates | 1 | 2010 | 77 | 0.310 |
Why?
|
| Receptor, EphB3 | 1 | 2009 | 3 | 0.310 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2007 | 65 | 0.300 |
Why?
|
| Hydantoins | 2 | 2006 | 5 | 0.300 |
Why?
|
| Mutant Proteins | 4 | 2015 | 112 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2016 | 1606 | 0.300 |
Why?
|
| Amidohydrolases | 1 | 2009 | 21 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 383 | 0.290 |
Why?
|
| Disease Models, Animal | 11 | 2025 | 4646 | 0.290 |
Why?
|
| Isomerism | 2 | 2021 | 23 | 0.290 |
Why?
|
| Kinetics | 10 | 2013 | 1085 | 0.280 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2008 | 12 | 0.280 |
Why?
|
| Triazoles | 1 | 2009 | 141 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 6 | 2017 | 2577 | 0.280 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 99 | 0.280 |
Why?
|
| Thiadiazoles | 1 | 2007 | 4 | 0.270 |
Why?
|
| Jurkat Cells | 5 | 2015 | 84 | 0.270 |
Why?
|
| Peptides | 6 | 2015 | 704 | 0.270 |
Why?
|
| Etomidate | 3 | 2011 | 7 | 0.260 |
Why?
|
| Substrate Specificity | 9 | 2015 | 284 | 0.250 |
Why?
|
| Muscular Atrophy, Spinal | 3 | 2017 | 46 | 0.250 |
Why?
|
| Antitubercular Agents | 3 | 2022 | 273 | 0.250 |
Why?
|
| Gene Expression Regulation | 5 | 2012 | 2323 | 0.250 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2025 | 61 | 0.250 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2007 | 45 | 0.250 |
Why?
|
| Piperazines | 1 | 2008 | 269 | 0.240 |
Why?
|
| Caco-2 Cells | 2 | 2024 | 86 | 0.230 |
Why?
|
| NAV1.7 Voltage-Gated Sodium Channel | 1 | 2025 | 3 | 0.230 |
Why?
|
| Phthalazines | 2 | 2017 | 20 | 0.230 |
Why?
|
| Nociception | 1 | 2025 | 13 | 0.230 |
Why?
|
| Biological Transport | 2 | 2019 | 328 | 0.230 |
Why?
|
| Fibroblast Growth Factors | 2 | 2025 | 171 | 0.230 |
Why?
|
| Transglutaminases | 1 | 2005 | 26 | 0.220 |
Why?
|
| Chalcone | 1 | 2005 | 1 | 0.220 |
Why?
|
| Caspase Inhibitors | 1 | 2005 | 30 | 0.220 |
Why?
|
| NAV1.6 Voltage-Gated Sodium Channel | 1 | 2025 | 27 | 0.220 |
Why?
|
| Hydrazines | 1 | 2005 | 28 | 0.220 |
Why?
|
| Nerve Growth Factor | 1 | 2005 | 19 | 0.220 |
Why?
|
| Neurites | 1 | 2005 | 43 | 0.220 |
Why?
|
| Diabetic Neuropathies | 1 | 2025 | 56 | 0.220 |
Why?
|
| Protein Biosynthesis | 5 | 2014 | 571 | 0.220 |
Why?
|
| Mesoridazine | 1 | 2004 | 1 | 0.220 |
Why?
|
| Sensory Receptor Cells | 1 | 2025 | 60 | 0.220 |
Why?
|
| Thiophenes | 1 | 2005 | 68 | 0.220 |
Why?
|
| Antiviral Agents | 3 | 2023 | 800 | 0.220 |
Why?
|
| Receptors, Serotonin | 1 | 2004 | 37 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2021 | 637 | 0.210 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2004 | 39 | 0.210 |
Why?
|
| Bacillus anthracis | 1 | 2025 | 45 | 0.210 |
Why?
|
| Lactones | 2 | 2021 | 39 | 0.210 |
Why?
|
| Cyclooxygenase 2 | 2 | 2021 | 122 | 0.210 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2024 | 105 | 0.200 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2024 | 56 | 0.200 |
Why?
|
| Patents as Topic | 2 | 2017 | 18 | 0.200 |
Why?
|
| Benzodiazepinones | 1 | 2023 | 1 | 0.200 |
Why?
|
| In Vitro Techniques | 3 | 2014 | 806 | 0.200 |
Why?
|
| Staphylococcus aureus | 5 | 2021 | 478 | 0.200 |
Why?
|
| Herpesviridae | 1 | 2023 | 38 | 0.190 |
Why?
|
| Protozoan Proteins | 1 | 2024 | 127 | 0.190 |
Why?
|
| Amyloid beta-Protein Precursor | 3 | 2011 | 113 | 0.190 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 3 | 2013 | 32 | 0.190 |
Why?
|
| Lung Injury | 1 | 2024 | 123 | 0.190 |
Why?
|
| tau Proteins | 3 | 2013 | 257 | 0.180 |
Why?
|
| Superoxide Dismutase | 3 | 2014 | 174 | 0.180 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 258 | 0.180 |
Why?
|
| Cell Proliferation | 4 | 2021 | 2463 | 0.180 |
Why?
|
| Glucuronidase | 2 | 2012 | 32 | 0.180 |
Why?
|
| Sharks | 1 | 2021 | 4 | 0.180 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 4 | 2015 | 21 | 0.180 |
Why?
|
| Neuroprotective Agents | 4 | 2014 | 158 | 0.180 |
Why?
|
| Survival of Motor Neuron 1 Protein | 3 | 2017 | 20 | 0.180 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2022 | 86 | 0.180 |
Why?
|
| Butylated Hydroxyanisole | 1 | 2021 | 2 | 0.180 |
Why?
|
| Food Additives | 1 | 2021 | 5 | 0.170 |
Why?
|
| Methanol | 1 | 2021 | 11 | 0.170 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2021 | 22 | 0.170 |
Why?
|
| Phosphorylation | 7 | 2014 | 1571 | 0.170 |
Why?
|
| Plants | 1 | 2021 | 50 | 0.170 |
Why?
|
| Adrenal Cortex | 2 | 2011 | 10 | 0.170 |
Why?
|
| Pyrazines | 1 | 2021 | 79 | 0.170 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2021 | 42 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 6 | 2012 | 147 | 0.170 |
Why?
|
| Fibroblasts | 3 | 2021 | 852 | 0.160 |
Why?
|
| Carbon | 1 | 2021 | 100 | 0.160 |
Why?
|
| Neoplasms | 3 | 2021 | 2980 | 0.160 |
Why?
|
| Optical Imaging | 1 | 2021 | 76 | 0.160 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2015 | 112 | 0.160 |
Why?
|
| Biocompatible Materials | 1 | 2021 | 107 | 0.160 |
Why?
|
| Mice, Transgenic | 8 | 2025 | 2329 | 0.160 |
Why?
|
| Inflammation | 3 | 2020 | 1481 | 0.160 |
Why?
|
| Amyloid beta-Peptides | 5 | 2025 | 230 | 0.160 |
Why?
|
| Phospholipid Transfer Proteins | 2 | 2011 | 15 | 0.160 |
Why?
|
| Insulysin | 2 | 2010 | 3 | 0.160 |
Why?
|
| Protein Domains | 1 | 2021 | 252 | 0.150 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 208 | 0.150 |
Why?
|
| Cells, Cultured | 5 | 2015 | 2887 | 0.150 |
Why?
|
| Nucleotides | 1 | 2019 | 88 | 0.150 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 231 | 0.150 |
Why?
|
| Purines | 1 | 2019 | 115 | 0.150 |
Why?
|
| Amino Acid Sequence | 8 | 2015 | 2390 | 0.150 |
Why?
|
| Organoplatinum Compounds | 1 | 1999 | 34 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 9 | 2024 | 4693 | 0.140 |
Why?
|
| Molecular Conformation | 3 | 2013 | 96 | 0.140 |
Why?
|
| Amino Acid Substitution | 3 | 2015 | 404 | 0.140 |
Why?
|
| Photochemotherapy | 1 | 1999 | 40 | 0.140 |
Why?
|
| Parkinson Disease | 3 | 2015 | 721 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2022 | 851 | 0.130 |
Why?
|
| Francisella tularensis | 1 | 2017 | 16 | 0.130 |
Why?
|
| Caspases | 3 | 2010 | 152 | 0.130 |
Why?
|
| Molecular Probes | 1 | 2017 | 26 | 0.130 |
Why?
|
| Half-Life | 2 | 2017 | 148 | 0.130 |
Why?
|
| Isoxazoles | 1 | 2017 | 32 | 0.130 |
Why?
|
| RNA, Messenger | 7 | 2017 | 2553 | 0.130 |
Why?
|
| Myositis Ossificans | 2 | 2014 | 6 | 0.130 |
Why?
|
| Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2016 | 3 | 0.130 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 3463 | 0.120 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2016 | 24 | 0.120 |
Why?
|
| Benzamides | 1 | 2017 | 125 | 0.120 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 563 | 0.120 |
Why?
|
| Tuberculosis | 1 | 2022 | 555 | 0.120 |
Why?
|
| K562 Cells | 1 | 2016 | 97 | 0.120 |
Why?
|
| Rats | 7 | 2014 | 3378 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2017 | 360 | 0.120 |
Why?
|
| Baculoviridae | 2 | 2013 | 41 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2018 | 297 | 0.120 |
Why?
|
| Mass Spectrometry | 2 | 2016 | 358 | 0.120 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2015 | 4 | 0.120 |
Why?
|
| Drug Stability | 2 | 2012 | 56 | 0.110 |
Why?
|
| Fluorescence Resonance Energy Transfer | 3 | 2014 | 69 | 0.110 |
Why?
|
| Structural Homology, Protein | 1 | 2015 | 27 | 0.110 |
Why?
|
| Porphyrins | 1 | 2015 | 8 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2013 | 320 | 0.110 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2015 | 42 | 0.110 |
Why?
|
| Cloning, Molecular | 3 | 2013 | 778 | 0.110 |
Why?
|
| Computer Simulation | 2 | 2015 | 670 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2014 | 18 | 0.110 |
Why?
|
| Insulin | 2 | 2010 | 1143 | 0.110 |
Why?
|
| Indicators and Reagents | 2 | 2013 | 43 | 0.110 |
Why?
|
| Receptors, GABA-A | 2 | 2011 | 58 | 0.110 |
Why?
|
| Cysteine | 3 | 2014 | 137 | 0.100 |
Why?
|
| Coccidiostats | 1 | 2013 | 1 | 0.100 |
Why?
|
| eIF-2 Kinase | 1 | 2014 | 35 | 0.100 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2013 | 3 | 0.100 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2013 | 19 | 0.100 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2013 | 5 | 0.100 |
Why?
|
| Ruthenium | 1 | 2013 | 5 | 0.100 |
Why?
|
| Photochemical Processes | 1 | 2013 | 7 | 0.100 |
Why?
|
| Combinatorial Chemistry Techniques | 3 | 2008 | 15 | 0.100 |
Why?
|
| Crystallization | 1 | 2013 | 83 | 0.100 |
Why?
|
| Toxoplasma | 1 | 2013 | 18 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 93 | 0.100 |
Why?
|
| Mutation | 4 | 2021 | 6069 | 0.100 |
Why?
|
| Arabidopsis Proteins | 1 | 2013 | 59 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2017 | 558 | 0.090 |
Why?
|
| Glutamate Plasma Membrane Transport Proteins | 1 | 2012 | 4 | 0.090 |
Why?
|
| Neurons | 5 | 2025 | 1979 | 0.090 |
Why?
|
| HeLa Cells | 4 | 2021 | 689 | 0.090 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2014 | 158 | 0.090 |
Why?
|
| Tauopathies | 1 | 2013 | 73 | 0.090 |
Why?
|
| Astrocytes | 2 | 2014 | 268 | 0.090 |
Why?
|
| Oxyquinoline | 1 | 2012 | 1 | 0.090 |
Why?
|
| Caspase 8 | 1 | 2011 | 26 | 0.090 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2011 | 5 | 0.090 |
Why?
|
| Alkylation | 1 | 2011 | 10 | 0.090 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2012 | 38 | 0.090 |
Why?
|
| Photolysis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Reflex | 1 | 2011 | 35 | 0.090 |
Why?
|
| Glutamates | 1 | 2011 | 52 | 0.090 |
Why?
|
| Nitrogen | 1 | 2011 | 120 | 0.090 |
Why?
|
| Methicillin Resistance | 2 | 2002 | 116 | 0.080 |
Why?
|
| Proteolysis | 3 | 2021 | 198 | 0.080 |
Why?
|
| Tosylarginine Methyl Ester | 1 | 2010 | 1 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2012 | 340 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2010 | 25 | 0.080 |
Why?
|
| Cell Survival | 1 | 2013 | 832 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2013 | 824 | 0.080 |
Why?
|
| Spindle Apparatus | 1 | 2010 | 49 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 254 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 1546 | 0.080 |
Why?
|
| West Nile virus | 1 | 2012 | 122 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 1364 | 0.080 |
Why?
|
| Leukemia | 1 | 2013 | 375 | 0.080 |
Why?
|
| HLA-D Antigens | 2 | 2009 | 8 | 0.080 |
Why?
|
| PC12 Cells | 2 | 2012 | 23 | 0.080 |
Why?
|
| Teichoic Acids | 1 | 2010 | 9 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2014 | 552 | 0.080 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2010 | 13 | 0.080 |
Why?
|
| Neurotoxins | 1 | 2010 | 45 | 0.080 |
Why?
|
| Viral Proteins | 1 | 2012 | 337 | 0.080 |
Why?
|
| Enzyme Activation | 4 | 2014 | 576 | 0.080 |
Why?
|
| Catalytic Domain | 2 | 2025 | 160 | 0.080 |
Why?
|
| West Nile Fever | 1 | 2012 | 145 | 0.080 |
Why?
|
| Models, Chemical | 2 | 2007 | 78 | 0.080 |
Why?
|
| Mitosis | 1 | 2010 | 191 | 0.080 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 447 | 0.080 |
Why?
|
| Amination | 1 | 2009 | 1 | 0.080 |
Why?
|
| Lipid A | 1 | 2009 | 23 | 0.070 |
Why?
|
| Patch-Clamp Techniques | 2 | 2025 | 271 | 0.070 |
Why?
|
| Enzyme Activators | 1 | 2009 | 10 | 0.070 |
Why?
|
| HLA-DR Antigens | 1 | 2009 | 66 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2010 | 108 | 0.070 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 128 | 0.070 |
Why?
|
| Paroxetine | 2 | 2006 | 24 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2009 | 111 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2009 | 76 | 0.070 |
Why?
|
| Ossification, Heterotopic | 1 | 2008 | 36 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 965 | 0.070 |
Why?
|
| Retinal Diseases | 1 | 2010 | 144 | 0.070 |
Why?
|
| Neuroglia | 1 | 2010 | 219 | 0.070 |
Why?
|
| Biological Assay | 1 | 2008 | 105 | 0.070 |
Why?
|
| Superoxide Dismutase-1 | 3 | 2014 | 24 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 217 | 0.070 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 2006 | 25 | 0.070 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2007 | 6 | 0.060 |
Why?
|
| Anemia | 1 | 2011 | 352 | 0.060 |
Why?
|
| Bromobenzenes | 1 | 2006 | 1 | 0.060 |
Why?
|
| Male | 11 | 2025 | 64386 | 0.060 |
Why?
|
| Glucose | 1 | 2011 | 851 | 0.060 |
Why?
|
| Enzyme Stability | 3 | 2013 | 58 | 0.060 |
Why?
|
| Ammonia | 1 | 2006 | 67 | 0.060 |
Why?
|
| Erythromycin | 1 | 2006 | 20 | 0.060 |
Why?
|
| Drugs, Investigational | 1 | 2006 | 26 | 0.060 |
Why?
|
| Phosgene | 1 | 2006 | 3 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2013 | 1013 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2011 | 1340 | 0.060 |
Why?
|
| Light | 2 | 2013 | 167 | 0.060 |
Why?
|
| Sulfhydryl Compounds | 1 | 2005 | 54 | 0.060 |
Why?
|
| Acetylcysteine | 1 | 2006 | 79 | 0.060 |
Why?
|
| Chalcones | 1 | 2005 | 6 | 0.060 |
Why?
|
| Caseins | 1 | 2005 | 65 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2005 | 82 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 2 | 2008 | 1076 | 0.060 |
Why?
|
| TRPV Cation Channels | 1 | 2025 | 42 | 0.060 |
Why?
|
| Enzyme Induction | 1 | 2005 | 92 | 0.060 |
Why?
|
| Computational Biology | 1 | 2010 | 862 | 0.050 |
Why?
|
| Anxiety | 1 | 2011 | 1003 | 0.050 |
Why?
|
| Diet | 1 | 2011 | 1097 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2005 | 236 | 0.050 |
Why?
|
| Cell Death | 3 | 2014 | 227 | 0.050 |
Why?
|
| Dimercaprol | 1 | 2004 | 3 | 0.050 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2024 | 38 | 0.050 |
Why?
|
| Ligands | 3 | 2012 | 481 | 0.050 |
Why?
|
| Protein Conformation | 2 | 2018 | 732 | 0.050 |
Why?
|
| Ubiquitination | 2 | 2015 | 174 | 0.050 |
Why?
|
| Female | 8 | 2025 | 70274 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2011 | 1110 | 0.050 |
Why?
|
| Liver | 1 | 2011 | 1787 | 0.050 |
Why?
|
| Acrylamides | 1 | 2023 | 28 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2023 | 102 | 0.050 |
Why?
|
| Oximes | 1 | 2003 | 56 | 0.050 |
Why?
|
| Influenza A virus | 1 | 2024 | 142 | 0.050 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2025 | 240 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2008 | 703 | 0.050 |
Why?
|
| Adenosine Triphosphate | 3 | 2010 | 266 | 0.050 |
Why?
|
| 5' Untranslated Regions | 3 | 2010 | 58 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2005 | 267 | 0.050 |
Why?
|
| Action Potentials | 1 | 2025 | 469 | 0.050 |
Why?
|
| Coenzyme A | 1 | 2022 | 6 | 0.050 |
Why?
|
| Inosine | 1 | 2021 | 7 | 0.040 |
Why?
|
| Biosynthetic Pathways | 1 | 2022 | 31 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2021 | 44 | 0.040 |
Why?
|
| Water | 2 | 2013 | 185 | 0.040 |
Why?
|
| Phenylalanine | 1 | 2022 | 131 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2015 | 802 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2023 | 558 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2021 | 46 | 0.040 |
Why?
|
| Materials Testing | 1 | 2021 | 73 | 0.040 |
Why?
|
| Reptiles | 1 | 2000 | 2 | 0.040 |
Why?
|
| Fossils | 1 | 2000 | 7 | 0.040 |
Why?
|
| Xenopus laevis | 2 | 2011 | 112 | 0.040 |
Why?
|
| Particle Size | 1 | 2021 | 135 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 607 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2025 | 849 | 0.040 |
Why?
|
| Gene Expression | 2 | 2017 | 1481 | 0.040 |
Why?
|
| Hydrolysis | 2 | 2011 | 140 | 0.040 |
Why?
|
| Larva | 2 | 2011 | 239 | 0.040 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2019 | 9 | 0.040 |
Why?
|
| Thymidylate Synthase | 1 | 2019 | 20 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2010 | 300 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2012 | 690 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 2019 | 76 | 0.040 |
Why?
|
| Zebrafish | 2 | 2013 | 414 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2025 | 944 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 2012 | 140 | 0.040 |
Why?
|
| Infectious Anemia Virus, Equine | 1 | 1999 | 2 | 0.040 |
Why?
|
| Antioxidants | 1 | 2021 | 334 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 1999 | 41 | 0.040 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2018 | 10 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1317 | 0.040 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2018 | 40 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1804 | 0.030 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2017 | 29 | 0.030 |
Why?
|
| Solubility | 1 | 2017 | 117 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 716 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2003 | 990 | 0.030 |
Why?
|
| Cyclopentanes | 1 | 1997 | 21 | 0.030 |
Why?
|
| Protein Stability | 1 | 2017 | 164 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 303 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2014 | 3814 | 0.030 |
Why?
|
| Time Factors | 3 | 2011 | 6177 | 0.030 |
Why?
|
| Sf9 Cells | 1 | 2015 | 10 | 0.030 |
Why?
|
| NAD | 1 | 2015 | 52 | 0.030 |
Why?
|
| Oxygen | 1 | 1999 | 549 | 0.030 |
Why?
|
| HIV-1 | 1 | 1999 | 494 | 0.030 |
Why?
|
| Benzothiepins | 1 | 2014 | 1 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 235 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2015 | 65 | 0.030 |
Why?
|
| Aging | 2 | 2012 | 1236 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 2014 | 30 | 0.030 |
Why?
|
| Pilocarpine | 1 | 2014 | 10 | 0.030 |
Why?
|
| Anterior Horn Cells | 1 | 2014 | 2 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 2896 | 0.030 |
Why?
|
| Pimozide | 1 | 2013 | 7 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2014 | 54 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2013 | 13 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 113 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 2013 | 52 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2014 | 230 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 65 | 0.020 |
Why?
|
| Diamines | 1 | 2013 | 8 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2014 | 362 | 0.020 |
Why?
|
| Homologous Recombination | 1 | 2013 | 97 | 0.020 |
Why?
|
| Presenilin-1 | 1 | 2013 | 51 | 0.020 |
Why?
|
| Allosteric Site | 1 | 2013 | 12 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2013 | 124 | 0.020 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 127 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 60 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 135 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2013 | 84 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2013 | 43 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 208 | 0.020 |
Why?
|
| Body Patterning | 1 | 2013 | 121 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2013 | 189 | 0.020 |
Why?
|
| Fluorescence Polarization | 1 | 2012 | 9 | 0.020 |
Why?
|
| Spodoptera | 1 | 2012 | 28 | 0.020 |
Why?
|
| Fluorescein | 1 | 2012 | 39 | 0.020 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2013 | 124 | 0.020 |
Why?
|
| Opossums | 1 | 2012 | 8 | 0.020 |
Why?
|
| Serine Proteases | 1 | 2012 | 9 | 0.020 |
Why?
|
| Status Epilepticus | 1 | 2014 | 159 | 0.020 |
Why?
|
| Gene Order | 1 | 2012 | 81 | 0.020 |
Why?
|
| Octanols | 1 | 2011 | 2 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 196 | 0.020 |
Why?
|
| Guanosine Triphosphate | 1 | 2011 | 38 | 0.020 |
Why?
|
| Databases, Factual | 1 | 1997 | 1230 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2012 | 165 | 0.020 |
Why?
|
| Turpentine | 1 | 2011 | 3 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2011 | 84 | 0.020 |
Why?
|
| Hepcidins | 1 | 2011 | 26 | 0.020 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 37 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 488 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2012 | 492 | 0.020 |
Why?
|
| Anaphase-Promoting Complex-Cyclosome | 1 | 2010 | 18 | 0.020 |
Why?
|
| Metaphase | 1 | 2010 | 32 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 418 | 0.020 |
Why?
|
| Memory | 1 | 2013 | 306 | 0.020 |
Why?
|
| Xenopus | 1 | 2010 | 103 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2010 | 53 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2011 | 293 | 0.020 |
Why?
|
| Prodrugs | 1 | 2010 | 56 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 1000 | 0.020 |
Why?
|
| Buffers | 1 | 2010 | 27 | 0.020 |
Why?
|
| Phenylpyruvic Acids | 1 | 2010 | 1 | 0.020 |
Why?
|
| Absorption | 1 | 2010 | 49 | 0.020 |
Why?
|
| Uracil | 1 | 2010 | 12 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 89 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2010 | 79 | 0.020 |
Why?
|
| CHO Cells | 1 | 2010 | 151 | 0.020 |
Why?
|
| Toxicity Tests | 1 | 2010 | 34 | 0.020 |
Why?
|
| Electroretinography | 1 | 2010 | 96 | 0.020 |
Why?
|
| Peptide Library | 1 | 2010 | 55 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 65 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 41 | 0.020 |
Why?
|
| Microtubules | 1 | 2010 | 131 | 0.020 |
Why?
|
| Learning | 1 | 2013 | 353 | 0.020 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2010 | 24 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2012 | 310 | 0.020 |
Why?
|
| Zebrafish Proteins | 1 | 2011 | 131 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 361 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 2010 | 108 | 0.020 |
Why?
|
| Proline | 1 | 2010 | 78 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 237 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2010 | 243 | 0.020 |
Why?
|
| Photoaffinity Labels | 1 | 2009 | 6 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 817 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 922 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2010 | 213 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 410 | 0.020 |
Why?
|
| Cattle | 2 | 2008 | 500 | 0.020 |
Why?
|
| Staurosporine | 1 | 2008 | 21 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 1454 | 0.020 |
Why?
|
| Quinazolines | 1 | 2010 | 176 | 0.020 |
Why?
|
| Postural Balance | 1 | 2010 | 134 | 0.020 |
Why?
|
| Radiometry | 1 | 2008 | 49 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 1209 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 783 | 0.020 |
Why?
|
| Dentate Gyrus | 1 | 2008 | 37 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 777 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2008 | 121 | 0.020 |
Why?
|
| Motor Skills | 1 | 2008 | 73 | 0.020 |
Why?
|
| Maze Learning | 1 | 2008 | 96 | 0.020 |
Why?
|
| Brain | 2 | 2012 | 3146 | 0.020 |
Why?
|
| Dinitrobenzenes | 1 | 2006 | 1 | 0.020 |
Why?
|
| Photochemistry | 1 | 2006 | 21 | 0.020 |
Why?
|
| Autophagy | 1 | 2010 | 419 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 542 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 598 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2006 | 61 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2011 | 997 | 0.010 |
Why?
|
| Macrophages | 1 | 2010 | 660 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2010 | 810 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 705 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 237 | 0.010 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2005 | 13 | 0.010 |
Why?
|
| Methylation | 1 | 2005 | 198 | 0.010 |
Why?
|
| Kidney | 1 | 2012 | 1278 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2013 | 12840 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2014 | 2404 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 4464 | 0.010 |
Why?
|
| Receptors, Transferrin | 1 | 2004 | 12 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 51 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 2004 | 110 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 212 | 0.010 |
Why?
|
| Hemolysis | 1 | 2003 | 87 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2006 | 688 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 718 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 1440 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 647 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1982 | 330 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2057 | 0.010 |
Why?
|
| Iron | 1 | 2004 | 306 | 0.010 |
Why?
|
| Thailand | 1 | 2000 | 47 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 448 | 0.010 |
Why?
|
| Leukemia Virus, Bovine | 1 | 1979 | 2 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2004 | 907 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2000 | 220 | 0.010 |
Why?
|
| Retroviridae | 1 | 1979 | 182 | 0.010 |
Why?
|
| Genes | 1 | 1979 | 308 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2000 | 306 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1979 | 452 | 0.010 |
Why?
|
| Chemistry, Organic | 1 | 1997 | 7 | 0.010 |
Why?
|
| DNA | 1 | 1982 | 1400 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1982 | 277 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1982 | 73 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1982 | 71 | 0.000 |
Why?
|
| Plasmids | 1 | 1982 | 446 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1979 | 295 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1982 | 776 | 0.000 |
Why?
|
| Base Sequence | 1 | 1982 | 2729 | 0.000 |
Why?
|